CAS 1708971-55-4

N-[5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-1,8-naphthyridine-1(2H)-carboxamide

CAS: 1708971-55-4

Formel: C₂₅H₃₀N₈O₄

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 506.5569

Ref: IN-DA003ARF

N-(5-Cyano-4-((2-Methoxyethyl)Amino)Pyridin-2-Yl)-7-Formyl-6-((4-Methyl-2-Oxopiperazin-1-Yl)Methyl)-3,4-Dihydro-1,8-Naphthyridine-1(2H)-Carboxamide

CAS: 1708971-55-4

N-(5-Cyano-4-((2-Methoxyethyl)Amino)Pyridin-2-Yl)-7-Formyl-6-((4-Methyl-2-Oxopiperazin-1-Yl)Methyl)-3,4-Dihydro-1,8-Naphthyridine-1(2H)-Carboxamide

Reinheit: 98%

Molekulargewicht: 506.56g/mol

Ref: 54-OR1023117

Roblitinib

CAS: 1708971-55-4

Roblitinib

Reinheit: ≥95%

Molekulargewicht: 506.56g/mol

Ref: 54-BUP05090

Roblitinib

CAS: 1708971-55-4

Roblitinib (FGF-401), an FGFR4 inhibitor, potentially blocks tumor growth by halting cell proliferation and survival.

Formel: C₂₅H₃₀N₈O₄

Reinheit: 97.27% - 99%

Farbe und Form: Solid

Molekulargewicht: 506.56

Ref: TM-T4235

FGF401

CAS: 1708971-55-4

FGF401 is a toll-like receptor modulator that binds to the toll-like receptor and blocks the binding of death protein and potential biomarker. It has been shown to have antiviral and antibacterial activities, as well as an ability to induce apoptosis in cancer cells. FGF401 has been shown to inhibit the growth of human urothelial carcinoma cells in vitro and in vivo by blocking the tyrosine kinase domain, which is necessary for cell proliferation. This drug also inhibits protein synthesis, leading to cell death. FGF401 may be useful for the treatment of infectious diseases, including cervical cancer and skin cancer.

Formel: C₂₅H₃₀N₈O₄

Reinheit: Min. 95%

Molekulargewicht: 506.56 g/mol

Ref: 3D-BF179498